FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018054089> ?p ?o ?g. }

• W2018054089 endingPage "472" @default.
• W2018054089 startingPage "469" @default.
• W2018054089 abstract "This survey estimated the frequency of use and adverse events associated with cisapride treatment of premature newborns in intensive care units. It was initiated in response to a warning issued in Canada cautioning against cisapride treatment of premature infants of <36 weeks' gestation and <3 months of age.Surveys were mailed to 105 neonatology training program directors to obtain the total number of neonatal intensive care unit (NICU) admissions, the number of admissions of infants of <36 weeks' gestation, the number of years that cisapride had been used, the estimated percent/number of premature patients treated with cisapride per year, and the frequency and nature of arrhythmias or other adverse events associated with cisapride treatment. Of 105 programs, 46 responded to a single mailing of the first survey. A second survey mailed to the 45 respondents to the first survey sought to determine the indications, diagnostic tests, and dosages used with cisapride treatment of premature newborns. Of the 45 programs, 26 responded to the second survey.More than 58 000 premature newborns of <36 weeks' gestation were admitted to the NICUs we surveyed, and approximately 19% were treated with cisapride. No deaths attributable to cisapride were reported among >11 000 preterm newborns treated. Three nonfatal arrhythmias were reported; two associated with 10-fold dosing errors and one with co-treatment with erythromycin, a macrolide antibiotic that reduces the metabolism of cisapride. Diarrhea was reported in 12 patients, and reversible liver enzyme changes were noted in one patient. Typically, cisapride treatment was started in dosages of 0.1 to 0.2 mg/kg/dose, repeated every 6 to 8 hours. Treatment usually was begun empirically, without a preceding study to document gastroesophageal reflux. The most frequent indications for cisapride treatment were choking or gagging, with associated apnea, bradycardia, and desaturation. Approximately 50% of patients had discontinued cisapride treatment before discharge. Eighty-four percent of clinicians judged cisapride to be effective for the problems being treated.Cisapride treatment of premature infants of <36 weeks' gestation and <3 months of age in NICUs appears to be widespread in the United States. Complications and adverse events were seen when cisapride was administered in excessive dosages or in combination with a drug that inhibits its metabolism and leads to increased serum concentrations. Severe toxicities such as arrhythmias were reported with a frequency of <1/11 000 NICU admissions. However, in a retrospective survey, episodes of toxicity, including mortality, attributable to cisapride may not have been recognized or reported." @default.
• W2018054089 created "2016-06-24" @default.
• W2018054089 creator A5036428450 @default.
• W2018054089 creator A5052769969 @default.
• W2018054089 creator A5054562914 @default.
• W2018054089 date "1999-02-01" @default.
• W2018054089 modified "2023-10-01" @default.
• W2018054089 title "Cisapride: A Survey of the Frequency of Use and Adverse Events in Premature Newborns" @default.
• W2018054089 cites W1519454443 @default.
• W2018054089 cites W1605377084 @default.
• W2018054089 cites W1965811138 @default.
• W2018054089 cites W1966797988 @default.
• W2018054089 cites W1974504640 @default.
• W2018054089 cites W1997088191 @default.
• W2018054089 cites W2004765164 @default.
• W2018054089 cites W2015573228 @default.
• W2018054089 cites W2017647037 @default.
• W2018054089 cites W2024400361 @default.
• W2018054089 cites W2029094948 @default.
• W2018054089 cites W2029666341 @default.
• W2018054089 cites W2035670442 @default.
• W2018054089 cites W2050614281 @default.
• W2018054089 cites W2077739675 @default.
• W2018054089 cites W2099961904 @default.
• W2018054089 cites W2143409873 @default.
• W2018054089 cites W2146110014 @default.
• W2018054089 cites W2255631083 @default.
• W2018054089 cites W2333621883 @default.
• W2018054089 cites W2374322379 @default.
• W2018054089 cites W4251812291 @default.
• W2018054089 cites W8942200 @default.
• W2018054089 cites W1971291480 @default.
• W2018054089 doi "https://doi.org/10.1542/peds.103.2.469" @default.
• W2018054089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9925843" @default.
• W2018054089 hasPublicationYear "1999" @default.
• W2018054089 type Work @default.
• W2018054089 sameAs 2018054089 @default.
• W2018054089 citedByCount "69" @default.
• W2018054089 countsByYear W20180540892012 @default.
• W2018054089 countsByYear W20180540892014 @default.
• W2018054089 countsByYear W20180540892015 @default.
• W2018054089 countsByYear W20180540892016 @default.
• W2018054089 countsByYear W20180540892017 @default.
• W2018054089 countsByYear W20180540892018 @default.
• W2018054089 countsByYear W20180540892022 @default.
• W2018054089 countsByYear W20180540892023 @default.
• W2018054089 crossrefType "journal-article" @default.
• W2018054089 hasAuthorship W2018054089A5036428450 @default.
• W2018054089 hasAuthorship W2018054089A5052769969 @default.
• W2018054089 hasAuthorship W2018054089A5054562914 @default.
• W2018054089 hasConcept C126322002 @default.
• W2018054089 hasConcept C162156334 @default.
• W2018054089 hasConcept C177713679 @default.
• W2018054089 hasConcept C187212893 @default.
• W2018054089 hasConcept C197934379 @default.
• W2018054089 hasConcept C2776119469 @default.
• W2018054089 hasConcept C2777091541 @default.
• W2018054089 hasConcept C2777247143 @default.
• W2018054089 hasConcept C2777288759 @default.
• W2018054089 hasConcept C2779234561 @default.
• W2018054089 hasConcept C2987404301 @default.
• W2018054089 hasConcept C46973012 @default.
• W2018054089 hasConcept C536800656 @default.
• W2018054089 hasConcept C54355233 @default.
• W2018054089 hasConcept C71924100 @default.
• W2018054089 hasConcept C86803240 @default.
• W2018054089 hasConceptScore W2018054089C126322002 @default.
• W2018054089 hasConceptScore W2018054089C162156334 @default.
• W2018054089 hasConceptScore W2018054089C177713679 @default.
• W2018054089 hasConceptScore W2018054089C187212893 @default.
• W2018054089 hasConceptScore W2018054089C197934379 @default.
• W2018054089 hasConceptScore W2018054089C2776119469 @default.
• W2018054089 hasConceptScore W2018054089C2777091541 @default.
• W2018054089 hasConceptScore W2018054089C2777247143 @default.
• W2018054089 hasConceptScore W2018054089C2777288759 @default.
• W2018054089 hasConceptScore W2018054089C2779234561 @default.
• W2018054089 hasConceptScore W2018054089C2987404301 @default.
• W2018054089 hasConceptScore W2018054089C46973012 @default.
• W2018054089 hasConceptScore W2018054089C536800656 @default.
• W2018054089 hasConceptScore W2018054089C54355233 @default.
• W2018054089 hasConceptScore W2018054089C71924100 @default.
• W2018054089 hasConceptScore W2018054089C86803240 @default.
• W2018054089 hasIssue "2" @default.
• W2018054089 hasLocation W20180540891 @default.
• W2018054089 hasLocation W20180540892 @default.
• W2018054089 hasOpenAccess W2018054089 @default.
• W2018054089 hasPrimaryLocation W20180540891 @default.
• W2018054089 hasRelatedWork W2009702056 @default.
• W2018054089 hasRelatedWork W2016895219 @default.
• W2018054089 hasRelatedWork W2018054089 @default.
• W2018054089 hasRelatedWork W2032380794 @default.
• W2018054089 hasRelatedWork W2057743042 @default.
• W2018054089 hasRelatedWork W2136528789 @default.
• W2018054089 hasRelatedWork W2580090070 @default.
• W2018054089 hasRelatedWork W2889536680 @default.
• W2018054089 hasRelatedWork W3134363801 @default.
• W2018054089 hasRelatedWork W3177386305 @default.
• W2018054089 hasVolume "103" @default.

• next